ALLMedicine™ IgA Nephropathy Center
Research & Reviews 2,955 results
https://doi.org/10.1016/j.clinthera.2021.03.009
Clinical Therapeutics; Zhao J, Ma F et. al.
Apr 17th, 2021 - This study assessed the long-term (10-year) tolerability and efficacy of a low-dose corticosteroid combined with mycophenolate mofetil (CS + MMF) in the treatment of immunoglobulin A nephropathy (IgAN) with stage 3/4 chronic kidney disease and pro...
https://doi.org/10.1186/s12882-021-02334-w 10.1038/ki.1985.120 10.2215/CJN.02670706 10.1007/s13730-018-0325-2 10.1679/aohc.73.113 10.2215/CJN.01970211 10.1002/path.5011 10.1093/ndt/5.10.847 10.1038/ki.2011.470 10.1053/j.ajkd.2008.03.021 10.1182/blood.V57.1.83.83 10.1001/jama.2011.1141 10.2215/CJN.11521210
BMC Nephrology; Taguchi S, Hidaka S et. al.
Apr 16th, 2021 - Macroscopic hematuria-associated acute kidney injury (AKI) is a well-known complication of immunoglobulin A (IgA) nephropathy. In such cases, intratubular obstruction by red blood cell (RBC) casts and acute tubular necrosis are mainly observed pat...
https://doi.org/10.1007/s10238-021-00703-1 10.1056/NEJMra1206793 10.1007/s10238-019-00602-6 10.1016/j.autrev.2015.05.009 10.1093/ndt/gfi166 10.1681/asn.2014101000 10.1007/s10157-018-1582-2 10.1007/s10157-018-1619-6 10.1371/journal.pone.0206865 10.3109/0886022x.2014.994408 10.5414/cn107854 10.1080/0886022x.2018.1532907 10.1007/s10157-018-1651-6 10.1681/asn.2012020187 10.1038/ki.2015.120 10.1038/ki.2015.153 10.1016/S0272-6386(98)70021-6 10.1053/j.ajkd.2010.02.337 10.1038/ki.2009.243 10.1016/j.kint.2017.02.003 10.1159/000492592 10.1007/s10238-019-00580-9 10.1146/annurev.publhealth.21.1.121 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.18637/jss.v042.i08 10.1097/MNH.0b013e3283436f5c 10.1371/journal.pone.0091756 10.3389/fimmu.2016.00117 10.1084/jem.20020542 10.1084/jem.191.7.1253 10.1016/j.imbio.2006.06.011 10.1038/ki.2014.63 10.1681/ASN.2016060647 10.1038/ki.2015.322
Clinical and Experimental Medicine; Tan L, Tang Y et. al.
Apr 10th, 2021 - Mesangial IgM deposition is found in patients with immunoglobulin A nephropathy (IgAN). This study aims to investigate the relationships between mesangial IgM deposition and disease progression in IgAN patients. A total of 1239 patients with biops...
https://doi.org/10.1007/s00281-021-00847-y 10.1038/nrdp.2016.1 10.1007/s00467-017-3699-z 10.1007/s00281-013-0411-7 10.1038/nrneph.2015.208 10.1016/j.ekir.2020.08.009 10.1016/j.kint.2018.02.030 10.1007/s00467-017-3652-1 10.1093/ndt/gfaa223 10.1016/j.kint.2018.11.048 10.1038/s41581-020-0286-5 10.1038/s41581-019-0227-3 10.1159/000381738 10.1038/s41586-020-2941-1 10.1126/science.aat5031 10.1016/j.celrep.2020.108525 10.1080/14789450.2017.1331738 10.1038/s41598-017-09393-w 10.1038/nrneph.2017.30 10.1681/ASN.2012101006 10.1038/srep26138 10.1371/journal.pone.0099006 10.1002/mrc.4573 10.1007/s11306-012-0489-2 10.1042/CS20171107 10.1016/j.dld.2018.11.021 10.1007/s00248-015-0592-9 10.1038/s41598-020-73035-x 10.3389/fcimb.2020.557368 10.1016/j.intimp.2020.107085 10.1186/s12882-020-01741-9 10.1371/journal.pone.0081636 10.1016/S0272-6386(99)70141-1 10.1093/ndt/15.5.619 10.1111/j.1523-1755.2004.00714.x 10.1016/s0140-6736(94)90875-3 10.2353/ajpath.2010.090428 10.1172/JCI45563 10.1681/ASN.2015080911 10.1093/ndt/gfy323 10.1093/ndt/gfw343 10.1681/ASN.2016050496 10.1038/nbt1250 10.1073/pnas.0609643104 10.1021/nl103427w 10.1038/nmeth.2835 10.1016/j.cell.2018.07.010 10.1007/s00428-019-02705-7 10.1681/ASN.2015020204 10.1016/j.kint.2019.08.029 10.1038/nature14539 10.1038/s41591-018-0300-7 10.1038/s41591-019-0447-x 10.1016/S0140-6736(18)31645-3 10.1148/radiol.2017170700 10.1001/jama.2017.14585 10.1038/nature24270 10.1038/s41586-019-1724-z 10.1038/s41591-018-0213-5 10.1038/s41563-019-0345-0 10.1016/j.compbiomed.2017.09.014 10.1016/j.compmedimag.2018.11.002 10.1038/s41591-019-0703-0 10.1038/s41591-018-0316-z 10.1093/bib/bbx044 10.1038/s41576-019-0122-6 10.1016/j.kint.2020.02.027 10.1093/jamia/ocx030 10.1038/s41586-019-1390-1 10.1007/s00134-017-4678-3 10.1186/s13054-019-2563-x 10.1038/s41746-019-0100-6 10.1016/S2213-2600(18)30300-X 10.1111/ajt.15351 10.21037/atm.2020.01.09 10.1371/journal.pone.0228597 10.1016/j.kint.2020.02.028 10.1038/s41591-018-0177-5 10.1053/j.gastro.2020.06.021 10.1038/s41591-019-0462-y 10.1038/s41581-019-0220-x 10.1016/j.ajpath.2019.05.019 10.1016/j.ekir.2019.04.008 10.1681/ASN.2019020144 10.1038/ki.2012.428 10.1681/ASN.2018121259 10.1016/j.kint.2020.08.006 10.1093/ndt/13.1.67 10.1016/j.compbiomed.2015.09.003 10.1093/ndt/gfv232 10.1053/j.ajkd.2019.02.016 10.1016/j.ebiom.2020.102657 10.1001/jamanetworkopen.2020.0265 10.1007/s12553-017-0179-1 10.1145/3298981 10.1038/s41587-019-0214-z 10.1038/nrg.2016.69 10.1016/j.ekir.2020.07.012 10.1016/j.kint.2020.04.042 10.1038/s41551-020-0578-x 10.1073/pnas.1717139115 10.1016/j.kint.2020.04.046
Seminars in Immunopathology; Bülow RD, Dimitrov D et. al.
Apr 9th, 2021 - IgA nephropathy (IgAN) is the most common glomerulonephritis. It is characterized by the deposition of immune complexes containing immunoglobulin A (IgA) in the kidney's glomeruli, triggering an inflammatory process. In many patients, the disease ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031432
PloS One; Mohd R, Mohammad Kazmin NE et. al.
Apr 8th, 2021 - IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term surv...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956709
Clinical and Experimental Nephrology; Yuzawa Y, Yamamoto R et. al.
Apr 20th, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,
Clinicaltrials.gov 3,001 results
https://doi.org/10.1016/j.clinthera.2021.03.009
Clinical Therapeutics; Zhao J, Ma F et. al.
Apr 17th, 2021 - This study assessed the long-term (10-year) tolerability and efficacy of a low-dose corticosteroid combined with mycophenolate mofetil (CS + MMF) in the treatment of immunoglobulin A nephropathy (IgAN) with stage 3/4 chronic kidney disease and pro...
https://doi.org/10.1186/s12882-021-02334-w 10.1038/ki.1985.120 10.2215/CJN.02670706 10.1007/s13730-018-0325-2 10.1679/aohc.73.113 10.2215/CJN.01970211 10.1002/path.5011 10.1093/ndt/5.10.847 10.1038/ki.2011.470 10.1053/j.ajkd.2008.03.021 10.1182/blood.V57.1.83.83 10.1001/jama.2011.1141 10.2215/CJN.11521210
BMC Nephrology; Taguchi S, Hidaka S et. al.
Apr 16th, 2021 - Macroscopic hematuria-associated acute kidney injury (AKI) is a well-known complication of immunoglobulin A (IgA) nephropathy. In such cases, intratubular obstruction by red blood cell (RBC) casts and acute tubular necrosis are mainly observed pat...
https://doi.org/10.1007/s10238-021-00703-1 10.1056/NEJMra1206793 10.1007/s10238-019-00602-6 10.1016/j.autrev.2015.05.009 10.1093/ndt/gfi166 10.1681/asn.2014101000 10.1007/s10157-018-1582-2 10.1007/s10157-018-1619-6 10.1371/journal.pone.0206865 10.3109/0886022x.2014.994408 10.5414/cn107854 10.1080/0886022x.2018.1532907 10.1007/s10157-018-1651-6 10.1681/asn.2012020187 10.1038/ki.2015.120 10.1038/ki.2015.153 10.1016/S0272-6386(98)70021-6 10.1053/j.ajkd.2010.02.337 10.1038/ki.2009.243 10.1016/j.kint.2017.02.003 10.1159/000492592 10.1007/s10238-019-00580-9 10.1146/annurev.publhealth.21.1.121 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.18637/jss.v042.i08 10.1097/MNH.0b013e3283436f5c 10.1371/journal.pone.0091756 10.3389/fimmu.2016.00117 10.1084/jem.20020542 10.1084/jem.191.7.1253 10.1016/j.imbio.2006.06.011 10.1038/ki.2014.63 10.1681/ASN.2016060647 10.1038/ki.2015.322
Clinical and Experimental Medicine; Tan L, Tang Y et. al.
Apr 10th, 2021 - Mesangial IgM deposition is found in patients with immunoglobulin A nephropathy (IgAN). This study aims to investigate the relationships between mesangial IgM deposition and disease progression in IgAN patients. A total of 1239 patients with biops...
https://doi.org/10.1007/s00281-021-00847-y 10.1038/nrdp.2016.1 10.1007/s00467-017-3699-z 10.1007/s00281-013-0411-7 10.1038/nrneph.2015.208 10.1016/j.ekir.2020.08.009 10.1016/j.kint.2018.02.030 10.1007/s00467-017-3652-1 10.1093/ndt/gfaa223 10.1016/j.kint.2018.11.048 10.1038/s41581-020-0286-5 10.1038/s41581-019-0227-3 10.1159/000381738 10.1038/s41586-020-2941-1 10.1126/science.aat5031 10.1016/j.celrep.2020.108525 10.1080/14789450.2017.1331738 10.1038/s41598-017-09393-w 10.1038/nrneph.2017.30 10.1681/ASN.2012101006 10.1038/srep26138 10.1371/journal.pone.0099006 10.1002/mrc.4573 10.1007/s11306-012-0489-2 10.1042/CS20171107 10.1016/j.dld.2018.11.021 10.1007/s00248-015-0592-9 10.1038/s41598-020-73035-x 10.3389/fcimb.2020.557368 10.1016/j.intimp.2020.107085 10.1186/s12882-020-01741-9 10.1371/journal.pone.0081636 10.1016/S0272-6386(99)70141-1 10.1093/ndt/15.5.619 10.1111/j.1523-1755.2004.00714.x 10.1016/s0140-6736(94)90875-3 10.2353/ajpath.2010.090428 10.1172/JCI45563 10.1681/ASN.2015080911 10.1093/ndt/gfy323 10.1093/ndt/gfw343 10.1681/ASN.2016050496 10.1038/nbt1250 10.1073/pnas.0609643104 10.1021/nl103427w 10.1038/nmeth.2835 10.1016/j.cell.2018.07.010 10.1007/s00428-019-02705-7 10.1681/ASN.2015020204 10.1016/j.kint.2019.08.029 10.1038/nature14539 10.1038/s41591-018-0300-7 10.1038/s41591-019-0447-x 10.1016/S0140-6736(18)31645-3 10.1148/radiol.2017170700 10.1001/jama.2017.14585 10.1038/nature24270 10.1038/s41586-019-1724-z 10.1038/s41591-018-0213-5 10.1038/s41563-019-0345-0 10.1016/j.compbiomed.2017.09.014 10.1016/j.compmedimag.2018.11.002 10.1038/s41591-019-0703-0 10.1038/s41591-018-0316-z 10.1093/bib/bbx044 10.1038/s41576-019-0122-6 10.1016/j.kint.2020.02.027 10.1093/jamia/ocx030 10.1038/s41586-019-1390-1 10.1007/s00134-017-4678-3 10.1186/s13054-019-2563-x 10.1038/s41746-019-0100-6 10.1016/S2213-2600(18)30300-X 10.1111/ajt.15351 10.21037/atm.2020.01.09 10.1371/journal.pone.0228597 10.1016/j.kint.2020.02.028 10.1038/s41591-018-0177-5 10.1053/j.gastro.2020.06.021 10.1038/s41591-019-0462-y 10.1038/s41581-019-0220-x 10.1016/j.ajpath.2019.05.019 10.1016/j.ekir.2019.04.008 10.1681/ASN.2019020144 10.1038/ki.2012.428 10.1681/ASN.2018121259 10.1016/j.kint.2020.08.006 10.1093/ndt/13.1.67 10.1016/j.compbiomed.2015.09.003 10.1093/ndt/gfv232 10.1053/j.ajkd.2019.02.016 10.1016/j.ebiom.2020.102657 10.1001/jamanetworkopen.2020.0265 10.1007/s12553-017-0179-1 10.1145/3298981 10.1038/s41587-019-0214-z 10.1038/nrg.2016.69 10.1016/j.ekir.2020.07.012 10.1016/j.kint.2020.04.042 10.1038/s41551-020-0578-x 10.1073/pnas.1717139115 10.1016/j.kint.2020.04.046
Seminars in Immunopathology; Bülow RD, Dimitrov D et. al.
Apr 9th, 2021 - IgA nephropathy (IgAN) is the most common glomerulonephritis. It is characterized by the deposition of immune complexes containing immunoglobulin A (IgA) in the kidney's glomeruli, triggering an inflammatory process. In many patients, the disease ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031432
PloS One; Mohd R, Mohammad Kazmin NE et. al.
Apr 8th, 2021 - IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term surv...
News 31 results
https://www.mdedge.com/fedprac/article/177898/hepatitis/hcv-hbv-and-hiv-associated-autoimmune-kidney-diseases
Mark S. Lesney
Oct 23rd, 2018 - Chronic viral infection can be associated with a variety of autoimmune kidney diseases, according to a review published in Rheumatic Disease Clinics. London_England/Thinkstock In particular, hepatitis C virus (HCV) infection can cause several kidn.
https://www.medscape.com/viewarticle/883905
Aug 6th, 2017 - A high rate of serious adverse events led to the premature termination of a clinical trial designed to evaluate the efficacy of oral methylprednisolone in patients with immunoglobulin A (IgA) nephropathy despite evidence of a statistically signifi...
https://www.medpagetoday.com/nephrology/generalnephrology/66990
Aug 1st, 2017 - Action Points Corticosteroid treatment in patients with IgA nephropathy was tied to an increased risk for serious adverse events. Note that most adverse events occurred during the first 3 months of treatment, and they were primarily driven by an e...
https://www.medscape.com/viewarticle/855965
Dec 14th, 2015 - The addition of an immunosuppressive regimen to ongoing comprehensive supportive care does not benefit patients with immunoglobulin A (IgA) nephropathy characterized by moderate proteinuria and chronic kidney disease stages 1 to 3, final results f...
https://reference.staging.medscape.com/viewarticle/849383_4
Aug 12th, 2015 - The patient meets the histopathologic criteria for solitary IgA nephropathy; the subsequent renal biopsy showed diffuse proliferative endocapillary glomerulonephritis with increased mesangial matrix and cellularity, capillary wall thickening, and ...
